Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock.
OBJECTIVE
To determine the effects of an intravenous bolus dose of a vasopressin analogue, terlipressin (1 mg), on systemic haemodynamic parameters and gastric mucosal perfusion (GMP) in patients with catecholamine-treated septic shock using a gastric tonometry and laser-Doppler flowmetry technique.


METHODS
Prospective open label study.


METHODS
Two multidisciplinary intensive care units.


METHODS
Fifteen patients with norepinephrine-treated septic shock.


METHODS
Every patient with mean arterial pressure between 50 and 55 mmHg treated with high dose norepinephrine received an intravenous bolus dose of terlipressin as last resort therapy. A laser-Doppler probe and tonometer were introduced into the gastric lumen.


RESULTS
Terlipressin produced a decrease in cardiac output ( p<0.05), a progressive increase in mean arterial pressure ( p<0.05) and in GMP, detected by laser-Doppler flowmetry ( p<0.05) over 30 min and sustained for at least 24 h. The ratio of GMP to systemic oxygen delivery increased after terlipressin bolus dose ( p<0.05). The gradient between gastric mucosal and arterial PCO(2) tended to be lower after terlipressin, and the difference was statistically significant ( p<0.05) after 8 h. Terlipressin administration significantly increased ( p<0.05) urine output compared to baseline and higher values were found at each set of measurement. The terlipressin-induced increase in urine output was associated with a significantly increased creatinine clearance ( p<0.05). Reduction of the high-dose norepinephrine was observed in all patients ( p<0.05).


CONCLUSIONS
Our findings showed that, in patients with norepinephrine-treated septic shock, terlipressin increased GMP, urine output and creatinine clearance by an increase in mean arterial pressure.
Morelli
Andrea
A
Department of Anaesthesiology and Intensive Care, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy. andrea.morelli@uniroma1.it
Rocco
Monica
M
Conti
Giorgio
G
Orecchioni
Alessandra
A
De Gaetano
Andrea
A
Cortese
Giuliana
G
Coluzzi
Flaminia
F
Vernaglione
Enrico
E
Pelaia
Paolo
P
Pietropaoli
Paolo
P
D000368:Aged; D002395:Catecholamines / Q000627:therapeutic use; D002407:Catheterization, Swan-Ganz; D004305:Dose-Response Relationship, Drug; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D007362:Intensive Care Units; D017078:Laser-Doppler Flowmetry; D008236:Lypressin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008297:Male; D008365:Manometry; D008875:Middle Aged; D011446:Prospective Studies; D011651:Pulmonary Artery / Q000187:drug effects*; D012772:Shock, Septic / Q000188:drug therapy / Q000503:physiopathology*; D000077585:Terlipressin; D014554:Urination / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D002395:Catecholamines; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin